Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.77−0.02 (-2.23%)
Close on Nov 20, 2026Market cap $99.29MP/E –Yield –
Organogenesis shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Organogenesis's shares outstanding was 129M at Jun 30, 2026. For fiscal 2025 it was 130M, down 1.1% from the year before. The highest annual figure on record is 134M in fiscal 2021.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 130M | -1.1% |
| FY2024 | Dec 31, 2024 | 132M | -0.8% |
| FY2023 | Dec 31, 2023 | 133M | +0.3% |
| FY2022 | Dec 31, 2022 | 132M | -1.0% |
| FY2021 | Dec 31, 2021 | 134M | +20.0% |
| FY2020 | Dec 31, 2020 | 111M | +19.9% |
| FY2019 | Dec 31, 2019 | 93M | +33.9% |
| FY2018 | Dec 31, 2018 | 69M | +8.5% |
| FY2017 | Dec 31, 2017 | 64M | +1.1% |
| FY2016 | Dec 31, 2016 | 63M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 129M | +1.4% |
| Q1 FY2026 | Mar 31, 2026 | 128M | +1.2% |
| Q4 FY2025 | Dec 31, 2025 | 141M | +8.7% |
| Q3 FY2025 | Sep 30, 2025 | 131M | -2.3% |
| Q2 FY2025 | Jun 30, 2025 | 127M | -4.3% |
| Q1 FY2025 | Mar 31, 2025 | 126M | -4.2% |
| Q4 FY2024 | Dec 31, 2024 | 130M | -2.2% |
| Q3 FY2024 | Sep 30, 2024 | 134M | +0.4% |
| Q2 FY2024 | Jun 30, 2024 | 133M | -0.4% |
| Q1 FY2024 | Mar 31, 2024 | 132M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | 133M | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | 133M | +0.9% |
| Q2 FY2023 | Jun 30, 2023 | 133M | +0.4% |
| Q1 FY2023 | Mar 31, 2023 | 131M | +1.8% |
| Q4 FY2022 | Dec 31, 2022 | 132M | -1.1% |
| Q3 FY2022 | Sep 30, 2022 | 132M | -1.2% |
| Q2 FY2022 | Jun 30, 2022 | 133M | -1.0% |
| Q1 FY2022 | Mar 31, 2022 | 129M | -3.5% |
| Q4 FY2021 | Dec 31, 2021 | 133M | +1.6% |
| Q3 FY2021 | Sep 30, 2021 | 134M | +23.4% |
| Q2 FY2021 | Jun 30, 2021 | 134M | +28.0% |
| Q1 FY2021 | Mar 31, 2021 | 133M | +27.7% |
| Q4 FY2020 | Dec 31, 2020 | 131M | +34.1% |
| Q3 FY2020 | Sep 30, 2020 | 108M | +17.6% |
| Q2 FY2020 | Jun 30, 2020 | 105M | +15.5% |
| Q1 FY2020 | Mar 31, 2020 | 104M | +15.3% |
| Q4 FY2019 | Dec 31, 2019 | 98M | +27.1% |
| Q3 FY2019 | Sep 30, 2019 | 92M | +32.8% |
| Q2 FY2019 | Jun 30, 2019 | 91M | +36.6% |
| Q1 FY2019 | Mar 31, 2019 | 91M | +40.9% |
| Q4 FY2018 | Dec 31, 2018 | 77M | +20.0% |
| Q3 FY2018 | Sep 30, 2018 | 69M | +8.5% |
| Q2 FY2018 | Jun 30, 2018 | 66M | +3.7% |
| Q1 FY2018 | Mar 31, 2018 | 64M | -3.5% |
| Q4 FY2017 | Dec 31, 2017 | 64M | +598.2% |
| Q3 FY2017 | Sep 30, 2017 | 64M | +753.9% |
| Q2 FY2017 | Jun 30, 2017 | 64M | – |
| Q1 FY2017 | Mar 31, 2017 | 67M | – |
| Q4 FY2016 | Dec 31, 2016 | 9M | – |
| Q3 FY2016 | Sep 30, 2016 | 8M | – |
See a number that looks wrong?